RecruitingPhase 3NCT05946564
A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Principal Investigator
- Alexandre KarrasAssistance Publique - Hôpitaux de Paris
- Intervention
- Pioglitazone (ACTOS®)(drug)
- Enrollment
- 126 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2023 – 2027
Study locations (24)
- CHU Amiens, Amiens, France
- CHU d'Angers, Angers, France
- CH de Boulogne sur Mer, Boulogne-sur-Mer, France
- CHU Brest - Hôpital de la Cavale Blanche, Brest, France
- CHU de Dijon, Dijon, France
- CHU de Grenoble - Hôpital Michalon site nord, Grenoble, France
- Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France
- Hopital Le Kremlin Bicetre - Aphp, Le Kremlin-Bicêtre, France
- AP-HM - Hôpital la Conception, Marseille, France
- CHU de Nantes - Hotel Dieu, Nantes, France
- CHU Pasteur 2 - Nice, Nice, France
- CHU Nîmes - Hôpital universitaire Caremeau, Nîmes, France
- AP-HP - Hôpital Cochin, Paris, France
- AP-HP - Necker enfants malades, Paris, France
- HEGP, Paris, France
- +9 more locations on ClinicalTrials.gov
Collaborators
Ministry of Health, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05946564 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →